Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-954 PK in Hepatic Impairment
NCT03277274Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of felcisetrag in gastroparesis and enteral feeding intolerance (EFI), sponsored by Takeda. Started Nov 2017; status: completed.
02
Drugs
felcisetrag
03
Conditions
gastroparesisenteral feeding intolerance (EFI)
Beyond the preview
Go deeper on NCT03277274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277274.